journal article·2018-10-31Open access

Ferulic acid modification enhances the anti-oxidation activity of natural Hb in vitro

Donglai Qi, Qian Li, Chen Chen, Xiang Wang

Abstract

During the development of artificial red blood cell (RBC) substitutes, oxidation side reaction is one of the major factors that hinder the application of haemoglobin (Hb)-based oxygen carriers (HBOCs). In order to avoid oxidation toxicity, we designed and prepared natural Hb conjugated with ferulic acid (FA) via simple chemical modification. In addition, the thiol groups on Hb surface were increased via the reaction of Hb with 2-iminothiolane (2-IT) and then modified with FA for the study of anti-oxidant ability. It was showed that Hb modified with FA (FA-Hb) had similar oxygen-binding capacity to natural Hb. Moreover, the anti-oxidant ability of FA-Hb in vitro in different systems was superior to natural Hb and in proportion to the degree of modification of FA. The results indicate that FA-Hb might have the potential to serve as a novel oxygen carrier with the capacity to reduce oxidative side reaction.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · Erythrocyte Function and Pathophysiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Environmental and Chemical Engineering, Tianjin Polytechnic University

Funding

National Natural Science Foundation of China

References (37)

Show source-provided references
1. Seifried E, Mueller MM. The present and future of transfusion medicine. Blood Transfus. 2011;9:371–376.
2. 10.1021/bm400074t10.1021/bm400074t ↗
3. 10.3109/10731199.2012.66240810.3109/10731199.2012.662408 ↗
4. 10.1038/nm0597-474b10.1038/nm0597-474b ↗
5. Chang TMS. Blood substitutes: principles, methods, products and clinical trials. Switzerland: S. Karger AG; 1997.10.1159/isbn.978-3-8055-6584-4 ↗
6. 10.1016/S1072-7515(98)00095-710.1016/S1072-7515(98)00095-7 ↗
7. 10.1016/S0301-4622(01)00194-610.1016/S0301-4622(01)00194-6 ↗
8. 10.1001/jama.282.19.185710.1001/jama.282.19.1857 ↗
9. 10.1056/NEJM20000601342220410.1056/NEJM200006013422204 ↗
10. 10.1152/ajpheart.01184.200410.1152/ajpheart.01184.2004 ↗
11. 10.1152/ajpheart.01004.200410.1152/ajpheart.01004.2004 ↗
12. 10.1002/adma.20150258110.1002/adma.201502581 ↗
13. 10.1371/journal.pone.011054110.1371/journal.pone.0110541 ↗
14. 10.1021/cr970143c10.1021/cr970143c ↗
15. 10.1182/blood.V98.12.331510.1182/blood.V98.12.3315 ↗
16. 10.1007/s10047020002510.1007/s100470200025 ↗
17. 10.1021/bi012104810.1021/bi0121048 ↗
18. 10.1016/0076-6879(90)86118-F10.1016/0076-6879(90)86118-F ↗
19. 10.1016/j.freeradbiomed.2005.07.00210.1016/j.freeradbiomed.2005.07.002 ↗
20. 10.1081/BIO-20006660610.1081/BIO-200066606 ↗
21. 10.1080/1073119090274224010.1080/10731190902742240 ↗
22. 10.1021/ja050339r10.1021/ja050339r ↗
23. 10.1021/bm500425610.1021/bm5004256 ↗
24. 10.1038/cdd.2013.11310.1038/cdd.2013.113 ↗
25. 10.2174/15701631280265079710.2174/157016312802650797 ↗
26. 10.1002/jsfa.187310.1002/jsfa.1873 ↗
27. 10.1080/0738855049049146710.1080/07388550490491467 ↗
28. 10.3109/21691401.2016.113848910.3109/21691401.2016.1138489 ↗
29. 10.1016/0076-6879(94)31019-X10.1016/0076-6879(94)31019-X ↗
30. 10.1007/s00216-002-1347-210.1007/s00216-002-1347-2 ↗
31. 10.1016/S0021-9258(17)31468-010.1016/S0021-9258(17)31468-0 ↗
32. 10.1016/S0006-291X(71)80260-710.1016/S0006-291X(71)80260-7 ↗
33. 10.1016/S0169-409X(99)00045-910.1016/S0169-409X(99)00045-9 ↗
34. 10.1021/bc700465v10.1021/bc700465v ↗
35. 10.1111/j.1537-2995.2009.02356.x10.1111/j.1537-2995.2009.02356.x ↗
36. 10.1017/S002966510800600910.1017/S0029665108006009 ↗
37. 10.1021/pr100252e10.1021/pr100252e ↗